Cargando…

EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients

Bladder cancer is a leading cause of morbidity and mortality worldwide. Currently, immunotherapy has become a worthwhile therapy for bladder cancer. Tumor mutation burden (TMB) has been regarded as the most prevalent biomarker to predict immunotherapy. Bladder cancer is reported to have the third hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Gongmin, Pei, Lijiao, Li, Yuan, Gou, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041765/ https://www.ncbi.nlm.nih.gov/pubmed/32012118 http://dx.doi.org/10.18632/aging.102728

Ejemplares similares

Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation
por: Luo, Mayao, et al.
Publicado: (2023)

Profiles of tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications
por: Zhu, Gongmin, et al.
Publicado: (2019)

Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
por: Xie, Xiaona, et al.
Publicado: (2021)

Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients
por: Peng, Linglong, et al.
Publicado: (2021)

USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma
por: Sun, Yuanyuan, et al.
Publicado: (2021)

Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

A robust immune-related lncRNA signature for the prognosis of human colorectal cancer
por: Zhu, Gongmin, et al.
Publicado: (2022)

Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients
por: Huang, Yili, et al.
Publicado: (2022)

CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma
por: Li, Zhou, et al.
Publicado: (2022)

Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum
por: López, María, et al.
Publicado: (2018)

Whole exome sequencing reveals EP300 mutation in mildly affected female: expansion of the spectrum
por: Sellars, Elizabeth A., et al.
Publicado: (2016)

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer
por: Lv, Jia, et al.
Publicado: (2020)

KALRN mutations promote antitumor immunity and immunotherapy response in cancer
por: Li, Mengyuan, et al.
Publicado: (2020)

The protective role of EP300 in monocrotaline-induced pulmonary hypertension
por: Yang, Lei, et al.
Publicado: (2023)

A Prognostic Model for Predicting Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Bladder Urothelial Carcinoma
por: Wang, Chengbang, et al.
Publicado: (2022)

Risk factors, follow-up, and treatment of urethral recurrence following radical cystectomy and urinary diversion for bladder cancer: a meta-analysis of 9498 patients
por: Li, Xinyuan, et al.
Publicado: (2017)

EP300 promotes ferroptosis via HSPA5 acetylation in pancreatic cancer
por: Wang, Yuan, et al.
Publicado: (2023)

CREBBP and EP300 mutational spectrum and clinical presentations in a cohort of Swedish patients with Rubinstein–Taybi syndrome
por: Wincent, Josephine, et al.
Publicado: (2015)

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
por: Zhu, Gongmin, et al.
Publicado: (2021)

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
por: Wang, Hao, et al.
Publicado: (2021)

Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis
por: Ma, Yao, et al.
Publicado: (2019)

C1QTNF6 Overexpression Acts as a Predictor of Poor Prognosis in Bladder Cancer Patients
por: Zhu, Xin, et al.
Publicado: (2020)

Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
por: Liu, Ning, et al.
Publicado: (2022)

CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300 mutated lymphomas
por: Veazey, Kylee J., et al.
Publicado: (2020)

Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity
por: Chen, Zuobing, et al.
Publicado: (2021)

CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis
por: Huang, Yao-Hui, et al.
Publicado: (2021)

Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors
por: Wang, Zi‐Ming, et al.
Publicado: (2021)

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer
por: Li, Man, et al.
Publicado: (2020)

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
por: Hsiehchen, David, et al.
Publicado: (2020)

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing
por: Cho, Junhun, et al.
Publicado: (2021)

Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer
por: Zhang, Zhao, et al.
Publicado: (2021)

Correlate tumor mutation burden with immune signatures in human cancers
por: Wang, Xiaosheng, et al.
Publicado: (2019)

KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer
por: Kim, Kee-Beom, et al.
Publicado: (2022)

CSMD1 Mutations Are Associated with Increased Mutational Burden, Favorable Prognosis, and Anti-Tumor Immunity in Gastric Cancer
por: Huang, Taobi, et al.
Publicado: (2021)

Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
por: Francica, Brian J., et al.
Publicado: (2023)

Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer
por: Wu, Zonglong, et al.
Publicado: (2020)

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients
por: Wang, Yanni, et al.
Publicado: (2021)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer
por: Harbin, Laura M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hnj9orbd8lv14nkn9cerrhfaek